Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
This retrospective study assessed the safety and efficacy of sirolimus, an mTOR inhibitor, combined with endocrine therapy in 36 patients with advanced hormone receptor-positive (HR+) breast cancer. The combination yielded a median progression-free survival (PFS) of 4.9 months and an objective response rate of 19.4%, with a clinical benefit rate
June 26, 2025
No Comments